Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care

N Engl J Med. 2021 Apr 1;384(13):1269-1271. doi: 10.1056/NEJMe2101983.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Esophageal Neoplasms* / drug therapy
  • Esophagogastric Junction
  • Humans
  • Nivolumab / adverse effects
  • Standard of Care
  • Stomach Neoplasms*

Substances

  • Nivolumab